|
Category: antioxidants
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Soluble in: |
| | water, 9.987e+004 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
|
Not determined
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | antioxidants |
| Recommendation for telmesteine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for telmesteine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | (4R)-3-ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 65946 |
| Pubchem (sid): | 135025373 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (4R)-3- | ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid | | 3,4- | thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- |
Articles:
| PubMed: | Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent. |
| PubMed: | A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis. |
| PubMed: | Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. |
| PubMed: | Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. |
| PubMed: | A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (XClair), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis. |
| PubMed: | Steroids versus other immune modulators in the management of allergic dermatoses. |
| PubMed: | A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. |
| PubMed: | A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. |
| PubMed: | Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat. |
| PubMed: | [Telemestein and variations in blood concentrations of lipoprotein A]. |
|